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Rat mesangial cell hypertrophy in response to transforming
growth factor-f31
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Rat mesangial cell hypertrophy in response to transforming growth
factor-al. Central features of progressive glomerular sclerosis are initial
glomerular hypertrophy and subsequent accumulation of extracellular
matrix proteins. Since TGF-/31 may play a key role in this glomerular
response to injury, the present study sought to explore further TGF-131
actions and regulated expression of its receptor in rat mesangial cells.
The rat TGF-p type II receptor (TGF-/3R11) homolog was cloned by
screening a rat kidney cDNA library with a human TGF-pRII cDNA
probe, and sequenced. Expression of this receptor subtype in rat
mesangial cells was then demonstrated by RNase protection assay, and
by Northern blot analysis of poly (A)+ RNA, TGF-/3R11 expression
was down-regulated in cells treated with exogenous TGF-131. Affinity
cross linking studies demonstrated presence of this receptor on cell
surface. Rat mesangial cells also expressed TGF-pl and autoinduction
by TGF-al was observed in the same cells, suggesting that this
polypeptide may act in an autocrine fashion on mesangial cells, and that
it may stimulate a positive autoamplification loop. TGF-/31 inhibited
mesangial cell proliferation and stimulated significant overall protein
and collagen production. Furthermore, mesangial cell size increased in
response to chronic TGF-/31 treatment. These findings demonstrate that
rat mesangial cells express key components of the TGF-f3 system and
raise the intriguing possibility that in the glomerular mesangium,
TGF-/3l may not only induce extracellular matrix synthesis, but may
also participate in the process of glomerular hypertrophy in response to
injury.
It has been suggested that progressive glomerular sclerosis,
commonly observed in renal diseases which advance to end-
stage renal failure, represents a final common response to injury
[1]. A prominent feature of progressive glomerular sclerosis is
the deposition of extracellular matrix proteins with eventual
obliteration of glomerular capillary tufts and the consequent
cessation of filtration [2]. The mechanisms mediating glomeru-
lar sclerosis are only partially understood. In the experimental
model of extensive renal ablation in the rat, the compensatory
increase in single nephron glomerular filtration rate in remnant
glomeruli is mediated partly by higher than normal single
nephron plasma flow rates and intracapillary hydraulic pres-
sures, and partly by glomerular hypertrophy [1]. This compen-
satory response appears to be maladaptive, in that it is associ-
ated with the development of progressive proteinuria and
glomerular damage. Similarly, in experimental diabetes mellitus
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in the rat, hemodynamic alterations and early hypertrophy are
associated with the development of progressive proteinuria,
glomerular sclerosis and loss of glomerultr function [31. In
patients, hypertrophy of more normal "remnant" glomeruli is
commonly observed in renal diseases where inhomogeneous
injury has resulted in a significant loss of functioning nephrons
[4]. Also, in patients with diabetic nephropathy, renal and
glomerular hypertrophy [5] and higher than normal glomerular
filtration rates [6] are frequently observed prior to the develop-
ment of significant proteinuria and glomerular sclerosis. Pre-
vention of glomerular capillary hypertension in experimental
models of glomerular sclerosis protects against the develop-
ment of progressive glomerular damage, suggesting that glomer-
ular capillary hypertension is causally linked to the develop-
ment of glomerular sclerosis [7]. It has also been argued that
glomerular hypertrophy, not glomerular capillary hypertension,
represents the more important causative factor in this process
[8]. Both mechanisms are probably related, and are likely to
involve biochemical mediators that signal cell hypertrophy and
extracellular matrix production.
With regard to the kidney, enhanced TGF-/31 expression and
TGF-/3l bioactivity has been documented in a model of acute
antithymocyte serum-induced glomerulonephritis [9] and in
experimental antiglomerular basement membrane antibody-
mediated crescentic glomerulonephritis [101; excess matrix
deposition was prevented in the former model with a neutral-
izing TGF-f31 antiserum [11]. These studies therefore support
the view that TGF-131 participates in the process of glomerular
matrix deposition in some forms of acute glomerulonephritis.
Findings by Border and Ruoslahti [12] furthermore suggest
enhanced glomerular expression of TGF-pl in experimental
diabetes mellitus in the rat, and the same group has reported a
marked decrease in TGF-/31 expression in acute experimental
glomerulonephritis in response to a reduction in protein intake
[13]. Taken together, these data suggest that TGF-f3 may be an
important factor participating in the excess extracellular matrix
deposition observed in a number of glomerular diseases.
Type p transforming growth factors (TGFs-p) are multifunc-
tional mediators which may play a role in progressive glomer-
ular sclerosis. Three distinct mammalian TGFs-3 have been
identified [14], TGF-131 being the most abundant isoform, which
are found in large quantities in platelets and bone, and produced
by most cells studied so far. TGFs-f3 are released from cells and
platelets in the latent form, latency being conferred by associ-
ation of active TGF-/3 after its initial cleavage from the
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propeptide with two binding proteins derived from the TGF-/3
precursor, and with one other latency conferring protein [15,
16]. Activation of TGFs-13 through proteolytic release of the
latency conferring proteins is required prior to its interaction
with cell-surface receptors [17, 18].
TGFs-/3 regulate diverse cellular functions, including prolif-
eration, differentiation and developmental processes [19]. In
many systems, the TGFs-f3 inhibit cell proliferation, findings
which have led to the theory that disruption of TGF-/3 actions
may result in unrestrained proliferation of cells [16]. Indeed,
tumor forming potential by some mammary epithelial cells
appears to be related to a failure of TGF-/3 receptor expression
[20, 21]. By contrast, enhanced expression of TGF-13 action has
been observed in wound healing, in the repair of vascular injury
[22], and in diseases associated with interstitial fibrosis, such as
pulmonary fibrosis [23], hepatic cirrhosis [24], and in the skin
lesions of systemic sclerosis [25]. Previous studies also impli-
cate TGF-/3 in the process of enhanced glomerular matrix
deposition [26]. In this regard, it is of importance that TGFs-
potently stimulate synthesis of a number of extracellular matrix
proteins by a variety of cells [26, 27], including glomerular
mesangial cells [28, 29], and blunt mechanisms involved in
extracellular matrix degradation [30, 31].
TGFs-/3 bind to specific cell surface receptors which mediate
their actions. Two TGF-/3 receptor subtypes with a reasonably
well-established role in signaling cell responses have been
described, namely a ---60 kDa protein (the type I receptor) and
a —85 kDa protein (the type II receptor) [211. A third receptor
subtype, the type III receptor, is a membrane anchored proteo-
glycan with a very short intracytoplasmic domain, which is not
thought to evoke a direct cell signaling response [32]. The type
IV receptor has been identified by radioligand binding studies in
rat pituitary cells, and unlike the other TGF-f3 receptors, it
appears also to bind activin and inhibin, which are considered
distantly related to TGF-f31 as members of the large TGF-/3
family. The biological significance of this type IV receptor
remains to be determined [33]. Recently, the high molecular
weight (—400 kDa) type V receptor has been identified and
purified from bovine liver plasma membranes, and demon-
strated to have a serine/threonine kinase activity [34]. The types
I, II, III, and V receptors co-express in most normal cell types
[35]. Based principally on information derived from cells not
expressing types I or II receptors, both of the smaller cell-
surface receptors appear to be involved in TGF-13l signal
transduction [21, 36], though the mechanism of TGF-f31 signal-
ing in cells was obscure until recently. Sequence information
for the type II receptor (TGF-pRII) was recently obtained after
expression cloning of its cDNA in COS cells [21]. Based on the
predicted amino acid sequence and on expression data, the
TGF-j3R11 is a membrane-bound protein with a single trans-
membrane spanning domain which binds TGF-/3l in a rather
short extracellular domain. The cytoplasmic domain of this
receptor contains sequence highly homologous with the serine/
threonine kinase family [21], though activation of kinase activ-
ity by ligand binding to the TGF-/3R11 has yet to be demon-
strated. The receptors I and II associate as interdependent
components of a heteromeric complex: receptor I requires
receptor II to bind TGF-/3, and receptor II requires receptor Ito
signal [37].
Given the potential importance of TGF-f3 in the process of the
glonierular response to injury, the present study sought to
further define TGF-f3 actions in mesangial cells. Because pro-
gressive glomerular sclerosis is most commonly studied in rat
models, the nucleotide sequence for the rat homolog of TGF-
/3R11 was first established. The study further demonstrates
down-regulation of TGF-13R11 expression by exogenous
TGF-J3l and presence of the TGF-/3R11 protein on the cell
surface, autoinduction of TGF-f3l expression and TGF-/31-
induced hypertrophy in rat glomerular mesangial cells. The
findings raise the intriguing possibility that TGF-J31 might play
a role in the process of glomerular hypertrophy in response to
injury.
Methods
RNA isolation and Northern blot hybridization
To obtain rat kidney RNA, whole kidneys from rats 1 day of
age were homogenized in 5.5 M guanidine isothiocyanate
(GTC); total RNA was isolated by ultracentrifugation on a
cesium-TFA gradient and poly (A)+ RNA recovered from
oligo(dT)-cellulose. Pooled neonatal rat cDNA was prepared by
reverse transcription of 5 jg of poly (A)+ RNA with Super-
script RT (GIBCO BRL). Total RNA from cultured rat mesan-
gial cells and human retinal epithelial cells (provided by V.
Reddy) were obtained by the same method described above.
For Northern blot analysis (Fig. 3), 3 pg poly (A)+ RNA
from rat mesangial cells incubated for 24 hours in the presence
or absence of 3 nglml TGF-pl purified to 95% homogeneity by
SDS-PAGE from porcine platelets (R&D Systems Inc., Minne-
sota, USA) was isolated and size fractionated on a 1% agarose-
0.37 M formaldehyde gel in 20 ifiM 3-(N-morpholino) propane-
sulfonic acid (MOPS), 5 m sodium acetate and 1 mM EDTA,
pH 7.0, transferred to a nylon membrane in 20x SSC (lx SSC,
150 mM NaCl, 15 m sodium citrate, pH 7.0) and UV-
crosslinked. Hybridization was done at high stringency in 5x
SSPE, 10 mri Tris-HC1, pH 8.0, 50% formamide, 2.5x Den-
hardt's solution, 100 g/m1 salmon sperm DNA at 42°C over-
night, followed by one 20 minute wash at room temperature
with 2x SSC, 0.1% SDS and two 30 minute washes at 60°C with
0.2x SSC, 0.1% SDS. The cloned rat TGF-13R11 cDNA probe
was labeled using the random primer labeling system (GIBCO
BRL). Aldolase probe was a full-length 1.4 kb cDNA from
ATCC (Rockville, Maryland, USA). The autoradiographs were
analyzed by laser densitometer (Molecular Dynamics, Sunny-
vale, California, USA).
Ten g of total RNA from mesangial cells were used for the
Northern analysis in Figure 5. The TGF-f31 probe was a 652 bp
Kpn I cDNA fragment obtained from a full-length 2.14 kb
TGF-/31 cDNA (ATCC) and subcloned into the pSPORT vec-
tor. The 13-actin probe was a full-length 2.0 kb human 13-actin
cDNA obtained from Clontech.
Polymerase chain reaction
PCR primers for the kinase domain of the recently cloned
human TGF-f3RII [21] were prepared: sense primer: 5'-CCGG-
GATCCGTGGCAGTCAAGATCTTr-3', antisense primer: 5'-
CCGCTGCAGGCTCUGAGGTCCCTGTG-3'. Total RNA
(3 tg) from the cultured human retinal epithelial cell was
reverse transcribed and the first strand cDNA was used for
amplification. To obtain sequence for the rat TGF-/3R11 the
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same primers were used, and pooled eDNA> 1 kb in size from
rat neonatal kidney served as the template for PCR. For
amplification, 10 pA of cDNA was combined with 87 1.d PCR
Mix: (10 /Ll lOx PCR buffer (Perkin-Elmer); 8 pA 2.5 mM
dNTPs, 10 pA of 10 mrvi MgCl, and 59 pA H20) containing 0.25
M (in 1 pA) of each PCR primer. The sample was then placed
into the PCR cycler and heated for five minutes to 94°C
followed by a temperature drop to 55°C. 2 U Taq polymerase
were then added with a 50 pA mineral oil overlay, followed by 30
temperature cycles each consisting of three periods as follows:
denature: 94°C for 45 seconds; anneal: 55°C for 60 seconds;
extend: 72°C for 60 seconds. Following PCR, the products were
separated on a 2% agarose gel. Products of the appropriate size
from both human and rat templates were subcloned into the TA
cloning vector pCR (Invitrogen) and sequenced using the
dideoxy chain termination method. The sequence of one of the
human clones was found to be identical to a 327 bp stretch in the
kinase domain of the published human TGF-f3R11 eDNA [21].
Cloning and sequencing of the rat TGF-/3R11 cDNA
To construct a cDNA library, 5 jg of poly (A)+ RNA from
neonatal rat kidney were reverse transcribed using Superscript
RT (BRL). The library was generated in pSPORT1 (GIBCO
BRL) from cDNA >1 kb in size. Blots from 5 x 1O indepen-
dent colonies were screened using the partial human TGF-/3R11
cDNA previously derived by PCR as the probe. Hybridization
was done in 5x SSPE, 10 mrs Tris-HC1, pH 8.0, 40% forma-
mide, 2.5x Denhardt's solution, and 100 g/ml salmon sperm
DNA at 42°C overnight, followed by one 20 minute wash at
room temperature with 2 x SSXC, 0.1% SDS and two 30 minute
washes at 68°C with 0.2x SSC, 0.1% SDS. Three positive
clones were identified and restriction analysis was done. For
sequencing, one clone was isolated and contained a cDNA
approximately 3.0 kb in length. Partially overlapping nested
deletion clones were prepared from the cDNA with the Erase-
a-Base kit (Promega), followed by sequencing of the clones
using the dideoxy chain termination technique [38]. Ambiguous
regions in the sequence were resolved by sequencing appropri-
ate antisense strands.
Solution hybridizationiRNase protection
RNase protection analysis was done using the RPA II kit
(Ambion) according to the manufacturer's instructions. Briefly,
the 32P-labeled antisense RNA probe was prepared from the
linearized plasmid containing a fragment of the newly cloned rat
TGF-$RII cDNA using T7 RNA polymerase, yielding a probe
423 nucleotides long. The probe contains rat TGF-/3R11 an-
tisense sequence 318 nucleotides in length, the remainder
representing vector antisense sequences at each end. Six, 80
and 10 g of total RNA from human retinal epithelial cells, rat
mesangial cells and neonatal rat kidney, respectively, were
hybridized with 1 to 4 x i05 cpm of the 32P-labeled probe.
Hybridization was for 16 to 18 hours at 42°C in 50% formamide,
5x SSPE, 0.1 M Tris, pH 7.4 and 50 ig/ml salmon sperm DNA.
The samples were then digested with RNase A/TI, and resolved
on a 6% acrylamide/7.7 M urea sequencing gel. A sample of
35S-labeled DNA previously subjected to sequencing by the
dideoxy chain termination method was loaded in adjacent lanes
as the molecular size marker.
Covalent labeling of TGF-/3 receptors
Rat mesangial cells were incubated for three hours at 4°C in
binding assay buffer [Hanks' balanced salt solution (HBSS),
40 mM Hepes (pH 7.4), 0.2 g/dl bovine serum albumin (BSA)
and 1 mi bacitracin] with 400 M '251-TGF-f31 (Collaborative
Biomedical Products) in the presence and absence of 100 nM
unlabeled TGF-f3l. The cells were then washed twice with
40 m Hepes (pH 7.4) in HBSS followed by incubation for one
hour at 4°C with covalent cross-linking reagent ethylene glycol
bis (succinimidyl succinate) in dimethyl sulfoxide at a final
concentration of 2.5 m in HBSS. The cross-linking reaction
was quenched by the addition of an equal volume of 400 msc
EDTA, 1 M Tris (pH 6.8). The cells were detached with a rubber
policeman, transferred to a test tube and washed twice by
centrifugation with 40 mr's Hepes (pH 7.4) in HBSS at 4°C. The
resulting pellet was resuspended in 100 ,td of sample buffer
[62.5 m Tris base, 5% SDS, 5% glycerol, 0.01% bromphenol
blue, /3-mercaptoethanol, 5 mr's EDTA (pH 6.8)], boiled
for five minutes and subjected to centrifugation at 13,000 x g for
30 minutes to remove particulate matter, followed by 10 to 20%
gradient SDS-PAGE. The gel was stained with Coomassie
Brilliant Blue (Bio-Rad) to visualize the molecular weight
markers, and destained prior to autoradiography.
Cell culture
To culture rat glomerular mesangial cells, glomeruli were
isolated from the renal cortex of 75 to 100 g female Sprague-
Dawley rats using standard sieving techniques, digested at 37°C
for 45 minutes with collagenase, 1 mg/ml (CLS 3, Worthington)
in HBSS, washed three times by centrifugation at 800 x g,
resuspended in RPMI 1640 medium containing 15% supple-
mented calf serum (Hyclone, Utah, USA), plated on 100 mm
plates (Corning) and incubated in a humidified atmosphere of
5% CO2 in air, at 37°C. The medium was changed every 48
hours. After 14 to 21 days in primary culture the cells were
detached from the plates with trypsinlEDTA (GIBCO BRL) and
replated at a 1:4 dilution. Subsequent passages were performed
every 10 to 14 days, when the cells were still subconfluent. Cells
between passages 3 and 6 were used for experiments described
herein.
1H]Thymidine incorporation
Cells were plated in 24-well dishes and incubated in medium
containing 15% SCS for five days. On day 6 the cells were fed
with fresh medium containing 2% serum in the presence of
increasing concentrations (0.03 to 3 ng/ml) of TGF-/3l. Wells
treated similarly but not containing TGF-f3l served as controls.
After 45 hours, the medium was removed, and cells were
exposed for three hours to [3Hjthymidine 1 pCilml in RPMI
1640 medium containing 2% SCS. The supernatant was re-
moved, and cells were extracted three times with ice-cold 6%
trichloroacetic acid (TCA). The cells were then washed once
with water-saturated ether, allowed to dry, and solubilized in
0.1 N NaOH. The solubilized material was counted in a Packard
liquid scintillation counter with 50% counting efficiency for
[3H].
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A
(.251) cgcgcgcgcacacgctcgcctgggggacggagccccagcctcctgcgcagctctcctcggccgccgggggc
(.180) ctcctccgggcctccgagctccggggatcgccggccacatctggcccgcacctctgcccagcgcgctccgggcggcgcaggcatcctgag
(-90) agggcgaggaataaoggcg.cagcccggggtccccgaggctcggttcgcggcgccccaggggccggtctatgacgagcgacgggggctgcc
1 ATGGGTCGGGGGCTGCTCCGGGGCCTGTGGCCGCTGCACATCGTCCTGTGGACGCGCATCGCCAGCACGATCCCGCCGCACGTTCCCAAG
M G R G I L R G L W P L H I V L W T R I A S T I P P H V P K (30)
(91) TCGGTTAACAGCGATCTGATGGCGGGTGACAACAGCGGTGCGGTCAAGCTTCCACAGCTGTGCAAGTTTTGCGACGTGACACTGTCCACT
S V N S D L P4 A G D N S G A V K L P Q I © K F © D V T L S T (60)
(181) IGTGACAACCAGAAGTCTTGCATGAGCAACTGCAGCGTCACCTCCATCTGTGAGAAGCCGCAGGAAGTCTGCGTGGCCGTGTGGAGGAAGJD N Q K S ©M S N s V T S I © E K P Q E V ©V A V W R K (90)
(271) AACGACAAGAACATTACTCTGGAGACCGTTTGCCACGACCCCAAGTTCACCTACCACGGCTTCACTCTGGAAGATGCCACTTCTCCCACG
N D K N I T I E T V © H D P K F T Y H G F T L E D A T S P T (120)
(361) TGCGTCATGAAGGAAAAGAAAAGGGCGGGCGAGACCTTCTTCATGTGCTCCTGTAACACAGAGGAGTGTAACGATTACATCATCTTTAAT©VMKEKKRAGETFFM©S©NTEE©NDYIIFN (150)
(451) GAAGAATACACCACCAGCAGTCCTGACCTGTTGCTGGTCATTATCCAAGTGACGGGCGTCAGCCTCCTGCCTCCGCTGGGGATTGCCATA
E E Y I T S S P D L L I V I I 0 V T G V S L L P P L G I A I (180)
(541) GCTGTCATTGCCATCTTCTACTGTTACCGTGTCCACCGGCAGCAGAAGTTGAGCCCCICCTGGGAGAGCAGCAAGCCCCGGAAGCTCATG
A V I A I F Y C Y R V H R Q Q K L S P S W E S S K P R K L M (210)
(631) GATTTCAGCGACAACTGCGCCATCATCCTGGAGGACGACCGCTCTGACATCAGCTCTACGTGCGCCAACAACATCAACCACAATACGGAA
D F S D N C A I I L E D D R S D I S S I C A N N I N H N T E (240)
(721) CTGCTGCCCATCGAGCTGGACACGCTGGTGGGGAAGGGCCGCTTCGCCGAGGTCTACAAGGCCAAGCTGAAGCAGAACACTTCAGAGCAG
L L P I E T L V G K G R F A E V Y K A K I K Q N T S E Q (270)
(811) TTTGAGACCGTGGCTGTCAAGATCTTCCCCTACGAGGAATACTCCTCGTGGAAAACGGAGAAGGACATCTTCTCTGACATCAACCTGAAA
F E T V A V K I F P Y E E Y S S W K I E K 0 I F S D I N L K (300)
(901) CACGAGAACATCCTGCAGTTCCTGACGGCCGAGGAGCGGAAGACGGAGATGGGCAAGCAGTACTGGCTGATCACGGCGTTTCATGCTAAG
H E N I L Q F L I A E E R K I E N G K Q Y W L I I A F H A K (330)
(991) GGCAACCTGCAGGAGTACCTCACTAGGCACGTCAICAGCTGGGAGGACCTGCGGAAGCTGGGCAGCTCCCTGGCCCGGGGCATCGCCCAT
G N L Q E Y L T R H V I S W E D I R K L G S S L A R G I A H (360)
(1081) CTGCACAGTGACCACACTCCTTGIGGGAGGCCCAAGATGCCCATIGTTCACAGGGACCTCAAGAGCTCTAACATCCTAGTAAGAAGCGAT
I H S D H T P C G R P K N P I V H R 0 I K S S N I L V R S D (390)
(1171) CTAACCTGTTGCCTGTGTGACTTCGGGTTGTCCTIGGGCCTGAGCCCTACTCTGTCTGTGGATGACCTGGCCAACAGCGGGCAGGTGGGA
L T C C I C D F G L S L G L S P 1 L S V 0 D L A N R G Q V G (420)
(1261) ACAGCGAGATACATGGCCCCGGAAGTTCTAGAATCCAGGATGAATTTGGAGAACATGGAGTCCTTCAAGCAGACGGAIGTCTACTCCATG
T A R Y N A P E V L E S R P4 N I E N P4 E S F K Q T D V V S N (450)
(1351) GCTCTAGTACTCTGGGAAATGACGTCGCGCTGCAACGCTGTGGGAGAAGTGAAAGATTATGAGCCCCCGTTTGGTTCCAGAGTGCGGGAG
A I V L W E N T S R C N A V G E V K D V E P P F G S R V R E (480)
(1441) CACCCCTGTGIGGAGAGCATGAAAGACAACGTGCTGAGAGACCGAGGACGGCCTGAAATCCCCAGCTTCTGGCTCAACCACCAGGGCATC
H P C V E S N K 0 N V I R D R G R P E I P S F W I N H Q G I (510)
(1531) GATCGTGTGTGAGACACTGACCGAGTGCTGGGACCACGACCCCGAGGCCCGTCTCACAGCCCAGTGTGTGGCAGAGCGCTTCAGTGAAQ I V C E I L I E C P4 D H D P E A R L I A Q C V A E R F S E (540)
(1621) CTGGAGCACCCAGATAGACTCTCCGGGAGGAGCTGCTCCCAGGAGAAGATTCCAGAAGACGGCTCCCIGAACACTACCAAATAGcttttt
L E H R L S G R S C S Q E K I P E 0 G S I N T T K Z (567)
(1711) ctgggcaggctgggcaagactccggaagtccgtcctctaaccaaagoccogaggtcagcaggattgctttcctgactgatgcttctggaa
(1801) aaccaaggacttgctcccttcttccctag
Fig. 1. A. The nucleotide and deduced amino acid sequences of the cDNA encoding the rat TGF-f3RII. The nucleotides and amino acids are
numbered at the beginning and at the end of each line, respectively. The open reading frame sequence is indicated by upper-case letters, with the
+ I position nucleotide denoting the start codon (ATG). An in-frame stop codon (TGA) is noted upstream of the initiator (ATG), at positions —19
to —21. The flanking untranslated nucleotide sequences are shown by lower-case letters. The extracellular cysteine residues are circled, and the
potential N-linked glycosylation sites are indicated by asterisks. The hydrophobic transmembrane spanning domain is underlined. Arrows enclose
the cytoplasmic serine/threonine kinase domain. B. Alignment of the amino acid sequences of the rat TGF-/3R11 homolog with the known human
and porcine sequences. The published porcine amino acid sequence is incomplete, and indicated by dashes. Asterisks denote the positions where
the rat cDNA sequence contains two extra amino acid residues. The shaded areas indicate amino acid identity.
BM.RGLLRGLWPLHIV:LWTRIAT:IPPHVPKSVNSD1LAGJGAVKLPQL:.iCKFCDV 1ST (60)
MGRGL LRG1WPLHIVLWTRIASTIPPHVJjKSVNJDMVTDNNGAVKPQLCKFCDVR ST (6)
MGRGLLIGLVPLHMV.LWTRIASt.IPPHVPKSVNSDMMVTD]NGAVKLPQL(KFCbVI ST (60)
Rat CDNQKSCMSNCSMTSICEKPQEVCVAVWRKNDJNITLETVCHDPKTYHGFML ED TSP (120)
Human CDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKILPYRmL EDAASPK (120)
Pig CDNQKSCESNCSITJCEKPQEVCVAVWRKNDENITITIETVC[DPKIIAYHGF4JDAAS K (120)
Rat V KEKK AGETFFM(5(INTEJECNDfrI1JEEYIT SS DLLLVIQVTGVSLLPPLGIAI
Human CIMKEKK PGETFFMC5(SSDE(NDMIIFSEEyfr SNPDLL LVIFQVTGSLLPPLGAI
pig CIMKERK SGETFFMCSCSSDECNDHIIFsEEyo NNPDLL LVIFQVTGVSLIPPLGIAI
Rat IAV]iJIFYCYRVHRQQKL SPSWEIKPRKLMJI1CAIILEDDRSDISSTCANNINHNTE
HUmanVIIIFYCYRVRQQKLSWIKKLMEFSEHCAIILEDDRSDISSTCANNINHNTE
Pig IAVII1TIIYCYRVHRQQKL_SPSWGKPRKLMEFSEHAIILEDDRSDISSTCANNINHNTE
LLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEE4SWKIKDIFSDINLK (300)
LLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKDRKDIFSDINLK woo)
LLPIELDTLVGKGRFAEVYKAKL1QNTSEQFETVAVKIFPYEEYASWKDRKDIFSD1____ (296)
LHS.DHT.PCG RPKMPIVH RD LKSS NI LVSIDLTC CL CDFG.LS LG[flSftLI
LHSO.HtPCG RP.KMPIVH RDLKSS NI LV(N[DLtC CL CDF.GLsLRJGY si
Rat TARYMAPEVLESRMNLEP4MESFKQTDVYSMAiLVLWEMTSRCNAVGEVK DYEP GS RE (480)
Human TARYMAPEVLESRMNLEP4AESFKQTbVYsMALvLWEMTS NAVGEVK(EPPF$( R (480)
1V..g:$4.KDNV..DRG)PEIPSFWLNHQGIQIIIVCETLTECWDHDPEARLTAQCV.AERFS.E:.
[VESMKDNVLRDRG[r RN S* SEWLNHQG IQjMiICE TLTE cw DHDpEA;RLTAQc.VAERF;s1
Rat LEHjb.RLSG.RSICSEKIpEDGSLNTTK (567)
Human LEHJLIDRLSGRSCSIEEKIPEDGSL NTTK (565)
FIg. 1. Continued
[3H]proline and [3H]leucine incorporation
For [3H]leucine and [3H]proline incorporation, cells were
treated as described above, except that only one concentration
of TGF-/31, namely 3 ng/ml, was used. Cells not treated with
TGF-f31 served as controls. [3H}proline (2 Ci/ml, New En-
gland Nuclear, Boston, Massachusetts, USA) with 50 jLg/ml
ascorbic acid (Sigma) was added 24 hours after initiation of
TGF-3l treatment. After an additional 24 hours, cell and media
proteins were precipitated with an equal volume of 12% ice-cold
TCA. The cells were scraped from the plates and transferred
together with the supernatant into 5 ml polystyrene tubes and
the precipitated material was sedimented at 4°C and 1000 x g
for 10 minutes. The material was washed three times with fresh
6% TCA and then solubilized in 2 ml of 0.2 N NaOH. A portion
from each sample was subjected to liquid scintillation counting.
The remainder was adjusted to contain NaC1 100 mM, Hepes 50
mM, CaCl2 3 mi, pH 7.4. Chromatographically-purified bacte-
rial collagenase 100 U/ml (Type III, C0255 Sigma) was then
added, followed by incubation for 12 hours at room temperature
[27]. Following collagenase digestion the proteins were again
TCA precipitated as described above, washed three times with
ice-cold TCA, solubilized in 0.2 N NaOH and subjected to liquid
scintillation counting. Collagenase-sensitive [3H}proline incor-
poration was defined as the difference between TCA precipita-
ble counts before and after collagenase digestion. On average,
collagenase-sensitive [3H]proline incorporation represented 50
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eight-hour incubation, the supernatant was removed, the cell
proteins precipitated on the plate with ice-cold 6% TCA and
washed three times with fresh TCA. The cells were then
washed once with water-saturated ether, drie'1, solubilized in
1 N NaOH and subjected to scintillation counting. For all
experiments, cell numbers were determined in replicate plates.
[3H]Proline and [3H]leucine incorporation were corrected for
cell number and are shown as the percent increase over
incorporation in cells not treated with TGF-/31.
Cell proliferation and relative cell size determination
Mesangial cells were incubated in the presence of 2% sup-
plemented calf serum with or without 3 ng/ml of TGF-f31 for 12
days. On days 1, 3 and 12 the cells were washed three times
with phosphate buffered saline (PBS), detached from the plates
with trypsinlEDTA, titurated to obtain a single cell suspension
and counted in a Coulter Counter (Hialeah, Florida, USA). On
day 12, cells similarly treated from 100 mm plates were also
washed, detached and resuspended at a density of 106 cells/ml
in PBS containing 2% SCS. The cells were then subjected,
without fixation, to flow cytometry with an Epics C analyzer
(Coulter, Epics Div.). Relative cell size for 5000 cells in each
sample was determined by quantification of forward light scat-
tering.
Results
TGF-/3RH cDNA
Fig. 2. Expression of TGF-f3RII in rat kidney and cultured rat mesan-
gial cells. Total RNA from cultured human retinal epithelial cells (lane
1), rat glomerular mesangial cells (lane 2), neonatal rat kidney (lane 3)
was hybridized in solution with a 32P-labeled rat TGF-/3R11 cDNA
probe followed by RNase digestion. Controls represent 32P-labeled rat
TGF-/3R11 cDNA probe hybridized with tRNA, followed by digestion
with RNase (lane 4), or without RNase treatment (lane 5). The rat
TGF-f3R11 probe contained 318 nucleotides (nt) of authentic rat TGF-
/3R11 sequence and as well as some vector sequence. The 318 nude-
otides of authentic rat TGF-pRIl were expected to hybridize fully with
rat (but not human) TGF-/3R11 mRNA, the vector sequence was not
expected to hybridize. Observed protected fragments were 318 nt in
size (lanes 2 and 3), demonstrating that mRNA for rat TGF-f3RII was
present in total RNA from cultured rat mesangial cells and from rat
kidney. As expected, no protected fragment was observed when the
probe was hybridized with total RNA from human cells (lane I) or with
tRNA (lane 4). The undigested probe (containing flanking vector
sequence) was 423 nt long (lane 5). Molecular size was determined from
a concurrently run cDNA sequencing reaction.
to 60% of total proline incorporation; the fraction of collage-
nase-sensitive material did not change with TGF-J3 treatment.
[3HjLeucine (1 pCi/mI) was added to the cells 40 hours after
initiation of TGF-f3 treatment. At the end of an additional
A human TGF-f3RII cDNA fragment 327 bp in length was
obtained by PCR, subcloned into pCR and sequenced. The
nucleotide sequence for this cDNA fragment was identical to
the appropriate segment of the published sequence for the
human TGF-/3R11 [21]. A rat cDNA fragment 318 bp in length
was obtained by PCR amplification of neonatal rat kidney
cDNA. A full-length rat TGF-/3R11 cDNA was cloned by
screening the neonatal rat kidney library. The nucleotide se-
quence including the flanking noncoding regions, and the de-
duced amino acid sequence of this cDNA are shown in Figure
1A. An open reading frame of 1701 nucleotides was identified,
corresponding to a protein of 567 amino acid residues. An
in-frame stop codon (TGA) was noted upstream of the initiator
(ATG). The predicted rat TGF-/3R11 protein contains twelve
extracellular cysteine residues which define the Ig-like do-
mains, which are 100% conserved between the species. Two
potential N-linked glycosylation sites are identified in the ex-
tracellular domain. At the level of the nucleotide sequence,
there is 85% sequence identity with the known human se-
quence, and 88% amino acid sequence identity. The published
portion of porcine amino acid sequence has 84% homology with
the rat TGF-f3RII. The predicted protein encoded by the rat
TGF-/3R11 has a single hydrophobic transmembrane spanning
domain. The rat sequence contains two extra amino acid. in the
intracellular serine/threonine kinase domain. Based on the
predicted amino acid sequence, the calculated molecular mass
for the protein is 64 kDa. Figure lB illustrates the degree of
homology between the rat, human and pig sequences.
Regulated expression of TGF-f3RII
Solution hybridization/RNase protection was performed us-
ing antisense RNA prepared from the rat TGF-3RII cDNA with
1 2
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Fig. 4. Covalent labeling of TGF-/3 receptors. Affinity cross linking of
'251-TGF-/31 to receptors on rat mesangial cells and separation by
SDS-PAGE in the presence (lane 1) or absence (lane 2) of 100 nM
unlabeled TGF-/31. Two specifically labeled bands are observed at
approximately 60 kDa (lower -4) and approximately 85 kDa (upper —4')
corresponding to the TGF-/3 type I and H receptors, respectively. The
heavy labeling of material at the top of the gel likely represents type III
proteoglycan TGF-p binding sites.
Fig. 3. Down-regulation of TGF-13R11 mRNA expression by TGF- j31 in
mesangial cells. Rat mesangial cells were incubated in the presence or
absence of TGF-/3l (3 ng/ml) for 24 hours. Poly (A)+ RNA was isolated
and 3 gflane was subjected to Northern blot hybridization with the
cloned rat TGF-/3R11 cDNA probe (upper panels) or with a human
aldolase probe (lower panels). A 5.5 kb mRNA (—4') hybridized
specifically with the TGF-j3RII probe. By laser densitometry, TGF-
PRII mRNA abundance was 2332 and 1713 arbitrary units for control
and TGF-/31 treated cells, respectively. The abundance of aldolase
mRNA was greater in TGF-131 treated cells compared to controls (1179
vs. 1992 units).
some flanking vector sequence. Based on the size of the
TGF-/3R11 eDNA probe, the expected size of the protected
fragment was 318 nucleotides. As shown in Figure 2, hybrid-
ization with the rat TGF-/3R11 antisense RNA probe protected a
fragment 318 nucleotides in length from RNase digestion. These
data therefore demonstrate expression of TGF-/3R11 mRNA in
cultured rat mesangial cells.
To determine whether the TGF-13R11 expression in rat me-
sangial cells was regulated by TGF-/31, the cells were treated
with and without exogenous TGF-j31 (3 ng!ml) for 24 hours.
Northern blots containing poly (A) + mRNA from these cells
(Fig. 3) demonstrated decreased TGF-/3R11 mRNA abundance
in cells treated with TGF-/31. By densitometry, the signal
strength for TGF-f3R11 mRNA was reduced —30% in cells
treated with TGF-/31, whereas that for aldolase increased
---40%. In studies not shown, f actin mRNA abundance also
increased in cells treated with TGF-f31. Thus, whereas mRNA
abundance for aldolase, /3-actin and TGF-/31 (see below) in-
creased in cells treated with TGF-/31, mRNA abundance for
TGF-f3R11 decreased. Down-regulation of TGF-f.3R11 mRNA
was also observed in glomerular endothelial cells treated with
exogenous TGF-/31 (data not shown).
Ident(fication of receptors with affinity for TGF-/3
Affinity cross-linking studies with 1251-TGF-/3l in rat mesan-
gial cells detected two distinct bands with molecular masses of
approximately 85 and 60 kDa corresponding with TGF-f3RII
and TGF-/3 type I receptor, respectively (Fig. 4). The heavy
labeling at the top of the gel likely represents Type III proteo-
glycan TGF-f3 binding sites.
Autoinduction of TGF-p1 mRNA in mesangial cells
On Northern blots, the TGF-/31 cDNA probe hybridized
exclusively with a 2.4 kb mRNA. Under basal conditions,
mesangial cells expressed the TGF-/3l mRNA, though mRNA
abundance was exceedingly low. However, treatment of rat
mesangial cells for as little as five hours with exogenous
TGF-f31 (2 ng/ml) resulted in a significant augmentation of
TGF-/31 mRNA abundance in the cells (Fig. 5).
1 2
Fig. 5. Autoinduction of TGF-f31 mRNA by TGF-$1 in mesangial cells.Quiescent mesangial cells were treated with TGF-/3l (3 ng/ml) for 5
hours. Total RNA was then harvested from the cells, followed by
Northern blot analysis with a human TGF-/31 cDNA probe (upper
panels) or with a human /3-actin probe (lower panels). Ten j.tg of total
RNA was loaded in each lane. A 2.4 kb mRNA (—*) hybridized
specifically with the TGF-/3l cDNA probe. TGF-/31 mRNA abundance
was greater in cells treated with TGF-131 (lane 2) compared to cells left
untreated (lane 1). Similar densities for the f3-actin signals in both lanes
indicate approximate equivalence of RNA loading.
Effect of TGF-/31 on mesangial cell [3H]thymidine
incorporation and proliferation
As shown in Figure 6, treatment of mesangial cells (in 2%
serum) for 48 hours with TGF-/31 significantly inhibited [3H]thy-
midine incorporation in a concentration dependent fashion by
comparison with cells not treated with TGF-f31. An inhibitory
effect was also observed in cells exposed to higher concentra-
tions (15%) serum (data not shown). In these studies TGF-f.3l
had no inhibitory or stimulatory effect on DNA synthesis in
quiescent mesangial cells cultured without serum (data not
shown). Proliferation of mesangial cells was observed over 12
days when they were grown in 2% serum. Cell proliferation was
almost completely inhibited in cells that were also exposed to
exogenous TGF-f31 (3 nglml) during this culture period (Fig. 7).
Effect of TGF-/31 on mesangial cell [3H]proline and
[3H]leucine incorporation
Whereas DNA synthesis and cell proliferation were inhibited
by TGF-pI, there was a consistent and significant stimulation of
protein synthesis, as determined by [3H]leucine incorporation
(Fig. 8). During the first 48 hours of TGF-/3l treatment, total
collagen synthesis, as determined by [3H]proline incorporation
into collagenase-sensitive proteins, was augmented to a similar
degree.
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Fig. 7. Inhibition of mesangial cell prol(ferasion by TGF-j31. Mesangial
cells were grown in 2% serum for up to. 12 days in the absence (0) or
presence (•) of TGF-/31, 3 ng/ml. Media were changed every 48 hours.
Data represent means of triplicate determinations SD for one repre-
sentative experiment. Two other similar experiments gave essentially
identical results.
Effect of TGF-131 treatment on mesangial cell size
Mesangial cells grown for 12 days in 2% serum in the absence
or presence of exogenous TGF-/31 were subjected to quantifi-
cation of forward light scattering, a measure of relative cell size,
by flow cytometry. As shown in Figure 9, the mean cell size was
significantly greater in cells treated with TGF-f31 compared to
untreated cells. Mean forward light scattering averaged 266
12 and 391 13 units (mean SD, N 3, P <0.01 by Student's
t-test).
Discussion
This study was undertaken to further clarify the potential role
of TGF-/3l as a mediator in the glomerular response to injury.
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Fig. 6. Inhibition of [3HJthymidine incorporation by TGF-f31 in cul-
tured rat mesangial cells. Mesangial cells grown in 2% serum were
exposed to various concentrations of TGF-/31 for 45 hours, followed by
[3H]thymidine incorporation into the cells for three hours. Under these
conditions, TGF-j31 inhibited [3H]thymidine incorporation in a concen-
tration-dependent fashion.
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Fig. S. Stimulation of [3HJleucine and (3HJproline incorporation by
TGF-f31, Cell number (A), [>Hjleucine (B) and collagenase-sensitive
[3H]proline (C) incorporation were determined for mesangial cells
cultured in 2% serum with or without TGF-pl (3 ng/ml). Data for
[3Hjleucine and [3H]proline incorporation were corrected for cell num-
ber. Data for six separate experiments, each done in triplicate, are
shown as the % change produced by TGF-/3l, compared to cells not
treated with TGF-f31 (means SEM, * P < 0.01, Student's t-test).
The nucleotide sequence for a full-length rat TGF-/3R11 eDNA
was first established. Rat glomerular mesangial cells in culture
expressed mRNA for TGF-/3R11 as well as TGF-131, and exog-
enous TGF-f31 significantly raised TGF-f31 mRNA abundance
in mesangial cells. Exogenous TGF-131 inhibited mesangial cell
DNA synthesis and proliferation, but augmented collagen and
overall cell protein synthesis in mesangial cells with a concom-
itant increase in mesangial cell size. The findings suggest that
TGF-f31, in addition to its previously reported effects on extra-
cellular matrix synthesis by mesangial cells [28, 29] may also
participate in the process of glomerular hypertrophy, and
furthermore, that this mediator may induce an autocrine ampli-
fication loop of TGF-$1 action through autoinduction of
TUF-/31 expression.
Though receptors for TGF-/3 are widely expressed, not all
cell types exhibit them on their cell surfaces [20, 21]. In murine
mesangial cells high affinity binding sites for TGF-/3 receptors
have been demonstrated, though the subtype of TGF-/3 receptor
expressed by glomerular mesangial cells was not clearly estab-
lished [28]. A human TGF-/3R11 cDNA was recently cloned and
found to be a member of the receptor serine/threonine kinase
family [21]. Using the published sequence information, human
and rat TGF-/3R11 cDNA fragments were prepared by PCR and
a full-length rat TGF-pRII homolog was cloned and sequenced.
The rat TGF-pRII homolog shares 85% nucleotide sequence
and 88% amino acid sequence identity with the known human
TGF-13R11 (Fig. 1 A and B). Rat species-specific sequence was
used in this study to demonstrate TGF-/3R11 expression in
a,
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Fig. 9. Mesangial cell hypertrophy in response to TGF-/31. Rat mesan-
gial cells grown under the same conditions as those shown in Figure 8
were detached from the plates and subjected to fiow-cytometry. As a
measure of cell size, forward light scattering (arbitrary units) was
determined for a total of 5000 cells in each sample. The dotted vertical
line corresponds to the mean cell size of cells not treated with TGF-f3l
(control). One representative experiment is shown. Two other experi-
ments gave essentially the same results.
mesangial cells by RNase protection assay and by Northern
blot analysis. These data therefore indicate that mesangial cells
in culture express the mRNA for the type II TGF-/3 receptor
serine/threonine kinase. The rat-specific sequence should be
useful for the study of TGF-f3RII receptor expression and
localization in rat models of glomerular disease. The finding that
the TGF-/3R11 mRNA abundance in rat mesangial cells is
reduced within 24 hours by exogenous TGF-/31 (Fig. 3) suggests
that TGF-/31 negatively regulates expression of its own receptor
at the level of transcription or mRNA stability. It is of interest
that reduced TGF-f3RII mRNA abundance was found in asso-
ciation with an overall increase in protein synthesis, and in
association with increased expression of "housekeeping" genes
like aldolase and /3 actin.
Affinity cross-linking studies (Fig. 4) detected two distinct
cell surface receptors for TGF-/31 in rat mesangial cells cone-
sponding to TGF-/3 type I and II receptors thought to be
involved in the binding and signal transduction of TGF-p by
association as a heteromenc complex [371. Thus, not only was
mRNA for TGF-pRII expressed in mesangial cells, but the
receptor protein was also expressed at the cell surface.
To explore the biological actions of TGF-/31 on glomerular
mesangial cells, evidence for TGF-/31 mRNA expression was
also sought, and cells were examined for potential regulation of
TGF-/31 mRNA abundance in response to TGF-/31 stimulation.
By Northern blot analysis, TGF-/31 mRNA was expressed by
rat mesangial cells, a finding supported by the recent report by
Kaname et aI 39]. In this study, TGF-f31 expression was at low
Forward light scatter, arbitrary units
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levels by quiescent mesangial cells. However, TGF-131 mRNA
abundance was significantly induced when the cells were
treated with exogenous TGF-f31. These findings indicate that
TGF-/31 mRNA is autoinduced by TGF-f31, suggesting that a
positive amplification loop for TGF-131 action is stimulated by
TGF-3l in these cells. Similar autoinduction of TGF-/3 expres-
sion has been demonstrated in human lung adenocarcinoma
(A549) cells and has been attributed to two regions in the TGF-13
promoter which are responsive to autoinduction and to phorbol
ester and which bind the AP-l transcription factor complex [40,
41]. However, given that TGF-/3 is secreted by most cells in the
inactive form, autoinduction of TGF-/31 synthesis cannot nec-
essarily be assumed to increase TGF-/31 action, since the
regulation of TGF-/3 activity may not reside solely in its level of
synthesis, but also at the level of activation/inactivation [42].
Nevertheless, the data in this study do indicate that TGF-/31
synthesis may be further augmented when the cells are treated
with TGF-f31. If mesangial cells have the capability of activating
TGF-f3l, the findings suggest that the mediator could act in a
purely autocrine fashion within the glomerular mesangium.
In mesangial cells grown in 2% serum, TGF-/3l inhibited
[3H]thymidine incorporation in a concentration-dependent
manner, and inhibited cell proliferation. TGF-/31 has been
shown to inhibit DNA synthesis and proliferation in response to
serum and diverse growth factors in a number of cell types, an
effect that may be related to dephosphorylation of the retino-
blastoma gene product [43]. It has been suggested that this
growth regulating mediator may play an important role in
suppressing cell proliferation under basal conditions in vivo,
and absence of TGF-/3 receptors and TGF-j3 suppression of
growth have been postulated to enhance tumorigenic potential
in some tumors of epithelial cell origin, such as mammary
carcinoma [20, 43]. However, TGF-/31 can also stimulate pro-
liferation of cells, and can act synergistically with other growth
factors to induce the transformed phenotype [44]. In munne
mesangial cells, the effect of TGF-/31 on proliferation was
dependent on cell density: at higher cell densities the mediator
stimulated growth, and at lower cell densities it was found to be
inhibitory [28]. It has been suggested that TGF5-/3 may function
as a cellular switch, tending to stimulate or inhibit proliferation
and other cell functions depending on the basal state of the cell
[16]. It therefore is tempting to speculate that TGF-f3 may act to
suppress proliferation of mesangial cells under conditions when
these cells are stimulated to proliferate, as might occur in the
presence of an acute proliferative glomerulonephritis, whereas
under conditions in which the mesangial cell growth is sup-
pressed the cells could be stimulated to grow.
A large number of prior publications have demonstrated
enhanced production of extracellular matrix material by a wide
variety of cells in response to TGF-/3 [27, 45]. Enhanced
synthesis of fibronectin, heparan sulfate proteoglycans and of
collagen by glomerular mesangial cells in Vitro has been dem-
onstrated [26, 29, 46]. In this study, overall collagen synthesis,
as determined by [3H]proline incorporation into collagenase-
sensitive proteins, was significantly increased during the first 48
hours of exposure of the cells to TGF-f3l. However, not only
was there enhanced proline incorporation into collagen, but
total protein synthesis rates were also augmented as indicated
by enhanced [3H]leucine incorporation (Fig. 8). Given the
enhanced protein synthesis rates in the presence of suppressed
cell proliferation, it was postulated that TGF-J31 must result in
cellular hypertrophy. Indeed, when assessed by forward light
scattering, mesangial cells treated with TGF-f31 foi 12 days
were found, on average, to be significantly larger than cells not
treated with TGF-/31 (Fig. 9). These findings are consistent with
the marked alteration in mesangial cell morphology in response
to TGF-f31 observed by MacKay et al [28]. Furthermore,
hypertrophy of vascular smooth muscle cells in response to
TGF-f31 treatment has also been reported [47].
In summary, the nucleotide and amino acid sequences for the
rat TGF-/3R11 were obtained; expression of the receptor in rat
mesangial cells was then demonstrated by RNase protection
and Northern blot analysis. TGF-pl down-regulated TGF-/3R11
mRNA expression. Affinity cross-linking studies detected two
distinct TGF-/3 receptors, namely type I and type II, on the
surface of rat mesangial cells. The finding that TGF-/3l is also
expressed and autoinduced by TGF-pl in the same cells sug-
gests that this polypeptide may act in an autocrine fashion on
mesangial cells, and that it may stimulate a positive autoampli-
fication loop. Though mesangial cell proliferation was inhibited
by TGF-/3l, a significant increase in protein and collagen
production was found and overall cell size increased in re-
sponse to TGF-f31 treatment. Taken together, these findings
suggest that in the glomerular mesangium, the components of
the TGF-J3 system are expressed in a regulated fashion, and that
TGF-f31 not only affects extracellular matrix synthesis, but may
also participate in the process of glomerular hypertrophy.
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